Glenn Heller

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 17 papers. Top paper: “Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer”.

Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4023

N/A

0.725DataRank · unranked

125 citations

Hira Rizvi, Andrew J. Plodkowski, Matthew D. Hellmann, Andrea Knežević, Glenn Heller +8 more

Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers

Journal of Thoracic Oncology(2022)10.1016/j.jtho.2022.11.022

N/A

0.695DataRank · unranked

102 citations

Antonio Marra, Jane Sze Yin Sui, Jessica Flynn, Soo‐Ryum Yang, Christina J. Falcon +14 more

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps5107

N/A

0.241DataRank · unranked

4 citations

Glenn Heller, Charles J. Ryan, David James VanderWeele, Lionel D. Lewis, Alan Tan +10 more

CD39 Identifies Tumor-Reactive CD8 T cells in Patients With Lung Cancer

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.01.24.477554

N/A

0.240DataRank · unranked

3 citations

Fathema Uddin, Levi Mangarin, Hira Rizvi, Anton Dobrin, Sam E. Tischfield +31 more

Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9100

N/A

0DataRank · unranked

0 citations

Antonio Marra, Soo‐Ryum Yang, Christina J. Falcon, Glenn Heller, Mark G. Kris +4 more

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100546

N/A

0DataRank · unranked

4 citations

Noura J. Choudhury, Fiona Ehrich, Tyler Beardslee, Danielle Brazel, Shannon Zhang +8 more

A modified net reclassification improvement statistic

Journal of Statistical Planning and Inference(2023)10.1016/j.jspi.2023.03.001

N/A

0DataRank · unranked

1 citations

Glenn Heller

Data from Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells In Vivo

(2023)10.1158/1078-0432.c.6519468

N/A

0DataRank · unranked

0 citations

Marco Rossi, Gudrun Ratzinger, Maria-Angeles de Cos, David J. Chung, Katherine S. Panageas +7 more

Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0803

N/A

0DataRank · unranked

10 citations

Olivia Bobek, Irenaeus C.C. Chan, Brian C. Miller, David W. Hillman, Glenn Heller +8 more

Measuring the impact of new risk factors within survival models

Journal of the Royal Statistical Society Series C (Applied Statistics)(2024)10.1093/jrsssc/qlae045

N/A

0DataRank · unranked

0 citations

Sean M. Devlin, Glenn Heller

Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases

Annals of Oncology(2025)10.1016/j.annonc.2025.06.001

N/A

0DataRank · unranked

9 citations

Mark Jeng, S Tischfield, J.S.Y. Sui, Dmitry Nemirovsky, Glenn Heller +9 more

A novel predictive model using changes in clinical and serum biomarkers and automated quantitative imaging for mCRPC patients treated with AR-directed therapy.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.5_suppl.264

N/A

0DataRank · unranked

0 citations

Jessica Flynn, Binsheng Zhao, Aseem Anand, Karl Sjöstrand, Steven M. Larson +7 more

Measuring the temporal prognostic utility of a baseline risk score

Lifetime Data Analysis(2020)10.1007/s10985-020-09503-3

N/A

0DataRank · unranked

1 citations

Mithat Gönen, Glenn Heller, Sean M. Devlin

Outcomes of Terminal Complement Blockade in Adults with High-Risk Transplant-Associated Thrombotic Microangiopathy: A Comparative Analysis

Transplantation and Cellular Therapy(2025)10.1016/j.jtct.2025.11.037

N/A

0DataRank · unranked

0 citations

Glenn Heller, Christina Cho, Joshua Fein, Parastoo B. Dahi, Gunjan L. Shah +14 more

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

European Urology Open Science(2021)10.1016/j.euros.2021.09.015

N/A

0DataRank · unranked

19 citations

Emmanuel S. Antonarakis, Tina Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan +22 more

Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.02.002

N/A

0DataRank · unranked

7 citations

Glenn Heller, Joseph Fox, Daniel C. Danila, Anders Bjartell, Lars Edenbrandt +4 more

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps194

N/A

0DataRank · unranked

5 citations

Glenn Heller, Charles J. Ryan, David James VanderWeele, Lionel D. Lewis, Alan Tan +10 more